- Featured Product
- KD/KO Validated
CXCL10/IP-10 Polyclonal antibody
CXCL10/IP-10 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (2)
Applications
IHC, ELISA and More (2)
Conjugate
Unconjugated
验证数据展示
经过测试的应用
Positive IHC detected in | human ovary tumor tissue, human hepatocirrhosis tissue, human nasopharyngeal carcinoma tissue, human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
推荐稀释比
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:200-1:800 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
10937-1-AP targets CXCL10/IP-10 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
Tested Applications | IHC, ELISA Application Description |
Cited Applications | WB, IHC, IF |
Tested Reactivity | human |
Cited Reactivity | human, mouse, rat |
Immunogen | CXCL10/IP-10 fusion protein Ag1369 种属同源性预测 |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Full Name | chemokine (C-X-C motif) ligand 10 |
Synonyms | CXCL10, CXCL10/IP10, IP10, CXCL10(1-73), CXCL 10 |
Calculated Molecular Weight | 11 kDa |
GenBank Accession Number | BC010954 |
Gene Symbol | CXCL10 |
Gene ID (NCBI) | 3627 |
RRID | AB_2088002 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
UNIPROT ID | P02778 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
实验方案
Product Specific Protocols | |
---|---|
IHC protocol for CXCL10/IP-10 antibody 10937-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
Cancer Lett PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation | ||
J Mater Chem B Magnetic hyperthermia induces effective and genuine immunogenic tumor cell death with respect to exogenous heating | ||
Front Immunol LRPPRC facilitates tumor progression and immune evasion through upregulation of m6A modification of PD-L1 mRNA in hepatocellular carcinoma | ||
Cancer Commun (Lond) KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. | ||
Am J Cancer Res Identification of potential immune-related circRNA-miRNA-mRNA regulatory network in cutaneous squamous cell carcinoma | ||
Front Immunol CD11c+ B Cells Participate in the Pathogenesis of Graves' Disease by Secreting Thyroid Autoantibodies and Cytokines. |